Basal cell adenoma is a rare benign salivary gland tumor. The majority of the cases arise in the main parotid gland. In this paper, we report a case of basal cell adenoma in the right accessory parotid gland. The patient was a 70-year-old female with a 30×30 mm, elastic-firm, subcutaneous tumor in the right mid-cheek region. Magnetic resonance imaging showed that the tumor was located above the masseter muscle anterior to the main parotid gland. Surgical resection was performed under local anesthesia. Histopathologically, the tumor was composed of solid, trabecular, and duct-like structures. Solid and trabecular structures were constituted of small isomorphic cells with hyperchromatic, round nuclei. The diagnosis of basal cell adenoma of the accessory parotid gland was established from these clinicopathological findings. We reviewed the recent Japanese literature and found that the development of basal cell adenoma in the accessory parotid gland is exceedingly rare and that the incidence of malignancy in accessory parotid gland tumors is higher than that previously reported in the parotid gland tumors.
We conducted a multi-center, retrospective study to evaluate the clinical effect of chemoradiotherapy (CRT) with paclitaxel (PTX) in patients with angiosarcoma. We compared 12 patients treated with PTX and 18 patients treated with docetaxel (DTX). The results showed identical response ratios for CRT with PTX and CRT with DTX. Among the patients treated with PTX, the response ratio decreased significantly when the radiation dose was less than 70 Gy. Serious adverse effects were less common in patients treated with PTX than in those treated with DTX. All the serious adverse events occurred in patients who received PTX doses equal to or over 70 mg/m2. In conclusion, when we reduced the PTX dose and completed target radiation dose, CRT with PTX achieved a response ratio identical to that of CRT with DTX, but with less toxicity.
From August 2013 to September 2014, we treated 58 patients (65 limbs) with great saphenous varicose veins by using endovenous laser abrasion (980-nm diode laser with bare-tip fiber). The treatment produced excellent results, and no serious adverse events occurred; however, complications such as pain and ecchymosis developed in approximately 70% of the patients. In the past decade, endovascular treatment of varicose veins, including endovenous laser abrasion and radiofrequency abrasion, has gained popularity as a new minimally invasive treatment. Herein, we report the efficacy and complications of endovascular treatment on the basis of our experience, with the hope that this method will be developed further for applications in dermatology in the near future.